PANDA-VAC
/ UNC Lineberger Comprehensive Cancer Center
- LARVOL DELTA
Home
Next
Prev
1 to 6
Of
6
Go to page
1
January 14, 2025
PANDA-VAC: Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab
(clinicaltrials.gov)
- P1 | N=6 | Not yet recruiting | Sponsor: UNC Lineberger Comprehensive Cancer Center | Trial primary completion date: Jun 2025 ➔ Jun 2026
Trial primary completion date • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • ALK • EGFR
May 07, 2024
PANDA-VAC: Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab
(clinicaltrials.gov)
- P1 | N=6 | Not yet recruiting | Sponsor: UNC Lineberger Comprehensive Cancer Center | Trial primary completion date: Jun 2024 ➔ Jun 2025
Trial primary completion date • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • ALK • EGFR
May 11, 2023
PANDA-VAC: Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab
(clinicaltrials.gov)
- P1 | N=6 | Not yet recruiting | Sponsor: UNC Lineberger Comprehensive Cancer Center | Trial primary completion date: Jun 2023 ➔ Jun 2024
Trial primary completion date • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • ALK • EGFR
May 19, 2022
PANDA-VAC: Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab
(clinicaltrials.gov)
- P1 | N=6 | Not yet recruiting | Sponsor: UNC Lineberger Comprehensive Cancer Center | Trial completion date: Oct 2032 ➔ Jun 2033 | Trial primary completion date: Oct 2022 ➔ Jun 2023
Trial completion date • Trial primary completion date • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • ALK • EGFR
July 08, 2021
PANDA-VAC: Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab
(clinicaltrials.gov)
- P1; N=6; Not yet recruiting; Sponsor: UNC Lineberger Comprehensive Cancer Center; Trial completion date: Apr 2031 ➔ Oct 2032; Trial primary completion date: Apr 2021 ➔ Oct 2022
Trial completion date • Trial primary completion date • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • ALK • EGFR
March 31, 2020
PANDA-VAC: Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab
(clinicaltrials.gov)
- P1; N=6; Not yet recruiting; Sponsor: UNC Lineberger Comprehensive Cancer Center; Initiation date: Feb 2020 ➔ Sep 2020
Trial initiation date • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Thoracic Cancer • EGFR
1 to 6
Of
6
Go to page
1